Search tips
Search criteria 


Logo of jtdLink to Publisher's site
J Thorac Dis. 2017 February; 9(2): E166–E167.
PMCID: PMC5334070

‘σήψις’ yesterday, sepsis nowadays: what’s changing?

Is my patient septic or not?—that is the question. Sepsis (from the ancient Greek, σήψις) is an “antique” medical issue, a multi-faced life threatening disease characterized by organ dysfunction due to a dis-regulated host response to infection (1). Hyper-inflammation and immunoparalysis (2) along with tissue damage caused by pathogens play a key role into the onset and progression of the disease.

Sepsis is a complex illness whose underlying pathophysiologic process is not completely discovered. Clinical manifestations of sepsis are various, related to the type of infection, the organ functional reserve and the genetic pattern of the patient (3). The worst manifestation of sepsis is septic shock, a state of circulatory failure (hypotension) and serious impairment of oxygen delivery and utilization (hyperlactacidemia) characterized by high mortality rate (1). Many other systems (respiratory, renal, cardiovascular, hepatic, hematologic, central nervous system) might be affected by septic process, frequently culminating in multi-organ failure.

Although thousand studies have been published on sepsis, they have produced conflicting evidence mainly due to the heterogeneous population investigated and the diagnostic inclusion criteria adopted. The epidemiology of sepsis is highly debated in terms of incidence and outcome, further the disease lacks of a universally accepted characterization conforming the entire scientific society.

Recently, an international task force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM) has reviewed definitions of sepsis and septic shock (1). The Sepsis-3 definition is founded on expert consensus process evaluating the current clinical evidence about sepsis-induced illness (1,4,5). Sepsis-3 criteria validity have been tested on a large retrospective registry of electronic health recorded data sets (4,5) and needs prospective validation from everyday clinical practice. Sepsis-3 definition collected the most solid evidence about sepsis manifestation and might be considered a cornerstone diagnostic tool for each physician.

Zhang and co-workers published a well-written and updated review (6) on current guidelines for the diagnosis and early identification of sepsis in the hospital. The authors summarized the history of sepsis definition and highlighted the conflicting application of each one since 1992 up to 2016.

The identification of septic patients proceeds from a clinical evaluation of non-specific signs and symptoms that can not be counted and summed to achieve a pre-defined diagnostic cut-off (7). In addition, scoring systems and screening tools (8-12) have failed to reliably diagnose sepsis.

The diagnosis of sepsis might be achieved only if signs and symptoms of the patients are contextualized into each illness episode, evaluating the impact of co-morbidities and recent health-related events on to the clinical condition observed (surgery, trauma or baseline medical disease) (1).

Zhang et al. (6) reviewed the principal points of the diagnostic steps to move for the diagnosis of sepsis. An important issue of the sepsis diagnostic algorithm is the early recognition and subsequently treatment of the source of infection. Source recognition is based on clinical examination, biochemical and radiologic test (13). Infection is the ‘primum movens’ of sepsis and innovative laboratory tests as Matrix Assisted Laser Desorption Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS), performed on biologic samples taken from the patient, allow to achieve an early microbiologic diagnosis (14). Early recognition of pathogens in sterile sites of the organism might be helpful to understand the clinical condition observed and to start with an early appropriate antimicrobial therapy. Early recognition and treatment of the infection represents a ‘conditio sine qua non’ sepsis can’t be averted (13).

The diagnosis of sepsis is not simple and we agree with Zhang et al. (6) about the risk of identifying false positive and negative septic patients. However we think that treating a false positive patient is better than neglecting a false negative septic ill. No goal directed therapy is more lethal than sepsis.

The definition of sepsis is a work in progress (1) and much more efforts are needed to completely understand all the features of the disease. Current evidence enounced by the international consensus conferences and guidelines (1,13) provides the clinicians all the possible keys efficiently treat critically ill septic patients. Many items are changed compared to the past and sepsis is no longer a matter for shamans: now is the time of disenchantment.



Provenance: This is an invited Commentary article commissioned by Editor-in-Chief Nanshan Zhong (Academician, Chinese Academy of Engineering. Guangzhou Institute of Respiratory Disease, Guangzhou, China).

Conflicts of Interest: The authors have no conflicts of interest to declare.


1. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:801-10. 10.1001/jama.2016.0287 [PMC free article] [PubMed] [Cross Ref]
2. Hotchkiss RS, Monneret G, Payen D.. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013;13:862-74. 10.1038/nri3552 [PMC free article] [PubMed] [Cross Ref]
3. Davenport EE, Burnham KL, Radhakrishnan J, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med 2016;4:259-71. 10.1016/S2213-2600(16)00046-1 [PMC free article] [PubMed] [Cross Ref]
4. Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:775-87. 10.1001/jama.2016.0289 [PMC free article] [PubMed] [Cross Ref]
5. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:762-74. 10.1001/jama.2016.0288 [PubMed] [Cross Ref]
6. Zhang Z, Smischney NJ, Zhang H, et al. AME evidence series 001-The Society for Translational Medicine: clinical practice guidelines for diagnosis and early identification of sepsis in the hospital. J Thorac Dis 2016;8:2654-65. 10.21037/jtd.2016.08.03 [PMC free article] [PubMed] [Cross Ref]
7. Kaukonen KM, Bailey M, Pilcher D, et al. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med 2015;372:1629-38. 10.1056/NEJMoa1415236 [PubMed] [Cross Ref]
8. Keep JW, Messmer AS, Sladden R, et al. National early warning score at Emergency Department triage may allow earlier identification of patients with severe sepsis and septic shock: a retrospective observational study. Emerg Med J 2016;33:37-41. 10.1136/emermed-2014-204465 [PubMed] [Cross Ref]
9. Gibot S, Béné MC, Noel R, et al. Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med 2012;186:65-71. 10.1164/rccm.201201-0037OC [PubMed] [Cross Ref]
10. Liu Z, Chen J, Liu Y, et al. A simple bioscore improves diagnostic accuracy of sepsis after surgery. J Surg Res 2016;200:290-7. 10.1016/j.jss.2015.07.022 [PubMed] [Cross Ref]
11. Mahieu LM, De Muynck AO, De Dooy JJ, et al. Prediction of nosocomial sepsis in neonates by means of a computer-weighted bedside scoring system (NOSEP score). Crit Care Med 2000;28:2026-33. 10.1097/00003246-200006000-00058 [PubMed] [Cross Ref]
12. Moore LJ, Jones SL, Kreiner LA, et al. Validation of a screening tool for the early identification of sepsis. J Trauma 2009;66:1539-46; discussion 1546-7. 10.1097/TA.0b013e3181a3ac4b [PubMed] [Cross Ref]
13. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228. 10.1007/s00134-012-2769-8 [PubMed] [Cross Ref]
14. Angeletti S. Matrix assisted laser desorption time of flight mass spectrometry (MALDI-TOF MS) in clinical microbiology. J Microbiol Methods 2016. [Epub ahead of print]. 10.1016/j.mimet.2016.09.003 [PubMed] [Cross Ref]

Articles from Journal of Thoracic Disease are provided here courtesy of AME Publications